Medigen Vaccine Biologics (ROCO:6547) Institutional Ownership: 3.34% (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6547 Medigen Vaccine Biologics Corp ROCO:6547
67 GF Score
Price NT$51.50
GF Value NT$58.95
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medigen Vaccine Biologics Institutional Ownership?

Medigen Vaccine Biologics ROCO:6547 -1.34% 67 Institutional Ownership is 3.34% as of Aug. 16, 2026. GuruFocus rates ROCO:6547 with a GF Score™ of 67/100 and a GF Value™ of NT$58.95 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Medigen Vaccine Biologics's institutional ownership is 3.34%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Medigen Vaccine Biologics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Medigen Vaccine Biologics's Float Percentage Of Total Shares Outstanding is 0.00%.

Medigen Vaccine Biologics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Medigen Vaccine Biologics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Vaccine Biologics Institutional Ownership Chart

Medigen Vaccine Biologics Historical Data

The historical data trend for Medigen Vaccine Biologics can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 5.21 3.49 3.25 3.25 3.25 3.26 3.25 3.27 3.34 3.34
ROCO:6547
67GF Score
Medigen Vaccine Biologics Corp ROCO:6547
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Vaccine Biologics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 3.34% mean?
Medigen Vaccine Biologics (ROCO:6547) has a Institutional Ownership of 3.34% as of Aug. 16, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Medigen Vaccine Biologics and its competitors.
Is Medigen Vaccine Biologics' Institutional Ownership too high?
Medigen Vaccine Biologics' current Institutional Ownership is 3.34%. Overall, Medigen Vaccine Biologics has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' Institutional Ownership compare to VRTX and REGN?
Medigen Vaccine Biologics' Institutional Ownership of 3.34% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Medigen Vaccine Biologics and its competitors. Medigen Vaccine Biologics's current Institutional Ownership is 3.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$58.95, compared to a current price of NT$51.50 — trading 12.6% below its estimated fair value. The current Institutional Ownership is 3.34%. Medigen Vaccine Biologics' overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current Institutional Ownership is 3.34% as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be undervalued. The current stock price of NT$51.50 is trading 12.6% below its estimated GF Value™ of NT$58.95. GuruFocus considers Medigen Vaccine Biologics to be Modestly Undervalued.

Key valuation signals for ROCO:6547:

  • Institutional Ownership: 3.34%
  • GF Value™: NT$58.95 vs. price of NT$51.50 (12.6% below fair value)
  • GF Score™: 67/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medigen Vaccine Biologics Business Description

Address 302 No. 68, Shengyi 3rd Road, Hsinchu County, Zhubei, TWN, 30261
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
67GF Score

Get the complete analysis for ROCO:6547

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$51.50
Price
NT$58.95
GF Value